PRNewswire (Mon, 6-Jul 9:00 AM ET)
Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 2-Jul 4:05 PM ET)
Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Fri, 5-Jun 2:56 PM ET)
Outset Medical to Present at RBC Global Healthcare Conference
Globe Newswire (Mon, 11-May 4:05 PM ET)
Outset Medical Reports First-Quarter Results
Globe Newswire (Thu, 7-May 4:02 PM ET)
Outset Medical to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
Globe Newswire (Mon, 27-Apr 4:05 PM ET)
FDA Clearance for Next-Gen Tablo Hemodialysis Marks Major Milestone for Outset Medical
Market Chameleon (Tue, 27-Jan 4:33 AM ET)
Outset Medical Grows Revenue 5% and Lowers Cash Burn as Tablo Expands to Over 1,000 Sites
Market Chameleon (Mon, 12-Jan 4:54 AM ET)
Outset Medical's 2025 Revenue Grows 5% Amidst Operational Efficiencies and Board Refresh
Market Chameleon (Mon, 12-Jan 4:12 AM ET)
Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
Outset Medical trades on the NASDAQ stock market under the symbol OM.
As of July 7, 2026, OM stock price declined to $4.79 with 125,700 million shares trading.
OM has a beta of 2.57, meaning it tends to be more sensitive to market movements. OM has a correlation of 0.07 to the broad based SPY ETF.
OM has a market cap of $88.76 million. This is considered a Micro Cap stock.
Last quarter Outset Medical reported $28 million in Revenue and -$.83 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.01.
In the last 3 years, OM traded as high as $314.40 and as low as $3.00.
The top ETF exchange traded funds that OM belongs to (by Net Assets): VTI, VXF, VTWO, IWC, ITOT.
OM has underperformed the market in the last year with a price return of -77.1% while the SPY ETF gained +20.8%. However, in the short term, OM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +17.4% vs +13.8% return in SPY. But in the last 2 weeks, OM shares have been beat by the market, returning -1.8% compared to an SPY return of +0.4%.
OM support price is $4.68 and resistance is $5.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OM shares will trade within this expected range on the day.
